The use of drug calendars for the diagnosis of cutaneous drug eruptions in the age of electronic medical records by Cohen, Philip R & Grossman, Marc E
UC Davis
Dermatology Online Journal
Title
The use of drug calendars for the diagnosis of cutaneous drug eruptions in the age of 
electronic medical records
Permalink
https://escholarship.org/uc/item/1b20z85r
Journal
Dermatology Online Journal, 26(2)
Authors
Cohen, Philip R
Grossman, Marc E
Publication Date
2020
License
https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0
eScholarship.org Powered by the California Digital Library
University of California
Volume 26 Number 2| February 2020| 
26(2):3
 
 
- 1 - 
Dermatology Online Journal  ||  Commentary 
The use of drug calendars for the diagnosis of cutaneous 
drug eruptions in the age of electronic medical records 
Philip R Cohen1,2 MD, Marc E Grossman3,4 MD 
Affiliations: 1Dermatologist, San Diego Family Dermatology, National City, California, USA, 2Department of Dermatology, Touro 
University California College of Osteopathic Medicine, Vallejo, California, USA, 3Department of Dermatology, Yale University 
School of Medicine, New Haven, Connecticut, USA, 4Department of Dermatology, Hofstra/Northwell Donald and Barbara Zucker 
School of Medicine, New Hyde Park, New York, USA. 
Corresponding Author: Philip R. Cohen MD, 10991 Twinleaf Court, San Diego, CA 92131, Email: mitehead@gmail.com 
 
 
 
Keywords: calendar, cutaneous, diagnosis, drug, electronic, 
eruption, medical, record 
 
Introduction 
The most common condition leading to a 
dermatology consultation in the hospital is a 
morbilliform drug eruption. Hospitalized patients 
routinely receive an average of 12.5 medications 
during the course of their hospitalization making it 
difficult to identify the causative agent of the drug 
hypersensitivity reaction [1]. The onset of a drug-
related skin rash usually takes place within days-to-
weeks of the start of the implicated drug making 
timing an important diagnostic tool. The clever 
clinician attempts to determine which drug was the 
culprit and then substitute and/or stop just one 
medication — not all of them. 
 
Discussion 
Drug history by clinician 
There is no substitute for a comprehensive, 
thorough, and reliable drug history by the clinician. 
Indeed, a complete drug history should be obtained, 
which includes the six “Ins” of drug use that were 
described by Dr Joseph Bikowski in 2009: 1) instilled 
(drops placed in the ears, eyes, or nose), 2) inhaled 
(nasal sprays and mists, inhalers, or nebulizers. 
Nebulizers in particular are used in cystic fibrosis and 
human immunodeficiency (HIV)-positive patients 
with resistant recurrent pneumonias and often 
contain inhaled antibiotics or aerosolized 
pentamidine, 3) injected (drugs given 
intramuscularly, subcutaneously, or intravenously), 
4) inserted (a drug inserted into any orifice, such as 
vaginal or anal suppositories), and 5) in secret 
(surreptitious self-administration of a legal 
medication, an illegal substance, or a recreational 
drug), [2]. Therefore, the complete drug history 
should include over the counter medications, non-
prescription drugs, vitamins, dietary supplements 
containing herbal or organic products, and 
alternative or complementary medications. 
Manual drug calendar 
The creation of a drug calendar or a graphical drug 
chart can assist in the task of determining the 
Abstract 
A morbilliform drug eruption is the most common 
condition leading to a dermatology consultation for 
a patient in the hospital. Timing is an important 
diagnostic tool since the onset of a skin rash usually 
takes place within days-to-weeks of the start of the 
implicated drug. A comprehensive, thorough, and 
reliable drug history by the clinician is essential. 
Therefore, to assist in the task of determining the 
causative medication of a new skin rash in a 
hospitalized patient, the creation of a drug calendar 
is recommended. The development of an electronic 
version of the drug calendar offers several benefits 
over the manual version. As the use of electronic 
medical records continues to become the standard in 
medicine, the electronic drug calendar will serve as 
an invaluable tool for the diagnosis of drug 
hypersensitivity. 
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causative medication of a new skin rash in a 
hospitalized patient [1]. Typically, the drug calendar 
is a labor-intensive, time-consuming paper chart 
with handwritten dates and medications. However, 
the drug calendar will not detect the surreptitious 
use of medication, the use or abuse of illegal 
substances, or even over-the-counter medications, 
vitamins, and supplements. Therefore, specific 
questioning of the patient may unmask these 
unusual causes of drug rashes.  
Electronic drug calendar 
An electronic version of a drug calendar can be 
created with the assistance of the information 
technology department of the hospital. The drug 
calendar would list the daily medications 
administered over days to weeks before the onset of 
a drug rash. The development of an electronic 
version of the drug calendar offers several benefits 
over the manual version. 
Universal availability of drug history 
The electronic drug calendar produced by the 
dermatology consultant is available to all members 
of the health care team. This includes not only the 
prescribing doctor, but also the pharmacist ordering 
the drug to the floor and the nurse dispensing the 
medication. In addition, it can be accessed from 
anywhere in the medical center. 
Medications received away from the bedside 
Electronic generation of the drug calendar should 
eliminate possible errors in transcription. In addition, 
the electronic drug calendar should include 
medications administered at sites other than the 
bedside. These would include drugs not only given 
for radiology studies, but also those administered 
during procedures performed by other clinicians 
such as cardiologists, surgeons, or other 
subspecialists. 
Several agents used by radiologists and radiation 
oncologists would be part of the electronic drug 
calendar. For example, iododerma — a dramatic 
vesiculo-pustular eruption of the face and hands — 
is a well-known skin rash from iodinated contrast 
media routinely reported on radiology procedure 
forms [3]. Also, it took years to relate nephrogenic 
systemic fibrosis to the gadolinium-based contrast 
agent administered intravenously during magnetic 
resonance imaging because gadolinium was 
considered to be safe and was not even listed on the 
procedure forms [4]. In addition, the clinician might 
suspect the severe cutaneous reaction referred to as 
EMPACT syndrome (erythema multiforme associated 
with phenytoin and cranial radiation therapy) in 
oncology patients who are concurrently receiving 
treatment with phenytoin and cranial radiotherapy 
for their brain tumor [5]. 
Drug eruptions can occur from medications that are 
given in the emergency room immediately before 
admission. For example, phytonadione (vitamin K1) 
injection can produce early or later onset, localized 
or diffuse skin reactions [6]. The administration of 
these medicines in a hospitalized patient with a new 
skin rash should be considered; an electronic drug 
calendar — which includes all medications received 
by the patient not only after admission but also while 
in the emergency room — would assist in the 
discovery of the causative drug. 
Preoperative, intraoperative, and postoperative 
topically administered medications — potentially 
unsuspected as the culprit of a drug rash — would 
also be identified in the electronic drug calendar. 
Disinfectants, such as chlorhexidine and povidone-
iodine, that are used to cleanse the skin before 
surgery can cause contact dermatitis [7]. Open 
wounds may have been irrigated with neomycin to 
decrease the possibility of infection may 
subsequently be associated with a cryptogenic drug 
rash; the use of this medication may not have been 
written on the procedure forms [8]. Also, topical 
antibiotics following surgery can be occult etiologies 
for skin rashes [7, 9]. 
Prior hospitalization drug history 
One can view records of drug calendars from 
previous hospitalizations for comparison to narrow 
the list of agents suspected of causing a 
hypersensitivity reaction or confirmation of a drug 
allergy not previously realized. This might be 
referred to as the inadvertent or accidental drug 
challenge. It is important to recognize drug allergy 
because it may be associated with visceral or 
systemic hypersensitivity reactions and because of 
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the morbidity and mortality from allergic reactions 
on subsequent exposure. 
Review of previous electronic drug calendars, 
especially in oncology patients, allows for 
recognition of drug hypersensitivity reactions 
potentiated by prior immunotherapy. Immune 
checkpoint inhibition by ipilimumab may predispose 
patients to hypersensitivity skin reactions with 
vemurafenib [10]. In addition, an activated immune 
response by anti-PD-1 antibody inhibition before 
either vemurafenib or ipilimumab might result in 
increased drug toxicity [11]. 
Drug-related laboratory abnormalities 
Certain medications may be more commonly 
associated with a laboratory abnormality. Therefore, 
they are more likely to be the culprit drug in 
hospitalized patients with a new skin rash and 
accompanying abnormal laboratory studies. Hence, 
the use of the electronic drug calendar may be of 
benefit to clinicians under these circumstances when 
they encounter patients with drug reactions or 
adverse cutaneous side effects or both. 
The drug calendar can be linked to a graphic display 
of the patient’s temperature, complete blood cell 
count including eosinophils, platelets, and 
neutrophils, and serum chemistries. This would allow 
early detection of eosinophilia, thrombocytopenia, 
leukopenia, elevated liver enzymes (suggestive of 
hepatitis), and elevated renal function studies 
(indicative of acute kidney failure). All of these 
changes can serve as clues to the temporal diagnosis 
of drug hypersensitivity. 
Drug dosage changes 
The drug calendar would also include the start and 
stoppage of medications and the change of dosage 
of medications. Stevens-Johnson syndrome and 
toxic epidermal necrolysis are well known to develop 
with a rapid escalation of the dose of lamotrigine 
(Lamictal), [12, 13]. In addition, the co-administration 
of certain medications, such as valproate and 
lamotrigine, increases the risk of hypersensitivity 
reaction to lamotrigine [13, 14].  
Generic and brand drug names 
An electronic drug calendar would make apparent 
not only brand names but also their generic names 
so that an allergen is not disguised or hidden in a 
combination medication. The itemization of the 
drugs in the calendar could also provide alerts to 
potential cross-reactions between medications such 
as penicillin and cephalosporins and between 
phenytoin, carbamazepine, and phenobarbital [15, 
16]. Indeed, future drug calendars might include 
pharmacogenomic biomarkers for the patient that 
suggests a genetic predisposition to severe adverse 
drug reactions such as HLA-B*15:02 (and carriers of 
HLA-A*31:01) and carbamazepine or HLA-B*57:01 
and abacavir [17, 18]. 
Virus-related drug reactions 
Several underlying viral diseases can increase the risk 
of drug hypersensitivity reactions. These include 
Epstein-Barr virus (EBV) and ampicillin, HIV and 
trimethoprim-sulfamethoxazole, and human 
herpesvirus (HHV)-6, HHV-7, EBV, and 
cytomegalovirus and the multitude of medications 
associated with drug rash eosinophilia and systemic 
symptoms (DRESS), [19-21]. The electronic drug 
calendar could highlight the medications that are 
associated with potential virus-related drug 
reactions. 
Look-alike and sound-alike drugs 
Lamictal (lamotrigine) and Lamisil (terbinafine) are 
found very close together on an alphabetical list of 
medications prescribed electronically and could be 
easily confused or accidentally typed into the 
electronic prescription pad. The high dosage of 
Lamictal 250mg per day, instead of Lamisil 250mg 
per day for tinea pedis, can result in Stevens-Johnson 
syndrome [22]. Therefore, it is helpful to have the 
patient or their family to bring in the pill bottles of 
medications to confirm they are the correct 
medications and that there was no pharmacy or 
prescribing error related to a look-alike 
(orthographic) or sound-alike (phonetic) similarity 
between drug names [23]. 
Drug eruption clinical mimics 
Immunocompromised patients may have 
morbilliform eruptions that morphologically mimic a 
drug hypersensitivity reaction. Bone marrow 
transplant patients may have either a viral illness, 
lymphocyte recovery eruption, or acute graft-versus 
host disease [24]. Therefore, even with the aid of an 
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electronic drug calendar and skin biopsy, 
establishing a definitive diagnosis of drug rash and 
determining which medication is responsible may be 
impossible when a drug rash is suspected in these 
individuals. 
Drug rash onset 
One rule commonly used by many clinicians, “last on, 
first off” refers to the most recently added 
medication is the most likely cause of the drug 
eruption and should be stopped first. Most drugs 
typically produce a rash from days to two weeks after 
onset. In contrast, allopurinol and anti-seizure 
medications can take four to six weeks to elicit an 
adverse cutaneous reaction after initiation of 
therapy. The electronic drug calendar would 
accurately provide the starting date of all 
medications. 
Concurrent corticosteroid administration 
The reduction of a daily corticosteroid dosage could 
be related to the onset of a drug eruption that relates  
to a long standing medication; the hypersensitivity 
was suppressed by the higher dosage of systemic 
corticosteroid and subsequently appeared during 
the tapering process. Hence, administration of 
systemic corticosteroids would have altered the 
usual time of onset of the drug rash. However, the  
taper of a course of systemic corticosteroid would be 
illustrated in an electronic drug calendar.  
Drug rash duration 
Once the diagnosis of drug rash has been clinically 
established, data provided by the electronic drug 
calendar regarding the potentially suspected drugs 
and listing the frequencies of these medications 
causing adverse cutaneous events would be useful 
for identifying the most likely offending agent. It is 
important to remember that eruptions continue for 
several days after a drug is stopped before there is 
improvement. Also, the time course to resolution 
may be even longer when the patient’s renal or 
hepatic function is compromised. 
 
Conclusion 
The electronic drug calendar could serve as an 
invaluable tool for the diagnosis of drug 
hypersensitivity by the dermatology hospitalist or 
any other clinician as the use of electronic medical 
records continues to become the standard in 
medicine. 
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